Amurka ta ba da shawarar "Dakata" kan Tallafin Johnson & Johnson COVID-19 Saboda Damuwa da Ruwan jini

Wadatacce

• Bita don

Cibiyoyin Kula da Cututtuka da Cututtuka (CDC) da Hukumar Abinci da Magunguna (FDA) suna ba da shawarar cewa a “dakata da gudanar da allurar rigakafin COVID-19 na Johnson & Johnson” duk da allurai miliyan 6.8 da aka riga aka ba su a cikin Amurka har zuwa yau. Labarin ya zo ta hanyar sanarwar hadin gwiwa wanda ke ba da shawarar masu kula da lafiya su daina amfani da allurar Johnson & Johnson har sai an sami sanarwa. (Mai alaƙa: Duk abin da kuke Bukatar Sanin Game da Alurar COVID-19 na Johnson & Johnson)

Wannan sabon shawarwarin shine sakamakon wani nau'in jini mai wuya amma mai tsananin ƙarfi wanda ake kira cerebral venous sinus thrombosis (CVST) ana samun sa a cikin wasu mutanen da suka karɓi allurar rigakafi musamman a Amurka, a cewar sanarwar. A wannan yanayin, “ba kasafai” na nufin mutane shida ne kawai aka bayar da rahoton su ba bayan allurar rigakafin jini daga cikin kusan allurai miliyan 7. A kowane hali, an ga ɗigon jini a haɗe tare da thrombocytopenia, aka ƙananan matakan platelet na jini (gutsuttsarin sel a cikin jininka wanda ke ba da damar jikinka ya zama ƙulli don tsayawa ko hana zubar jini). Ya zuwa yanzu, kawai shari'o'in da aka ruwaito na CVST da thrombocytopenia da ke bin allurar Johnson & Johnson sun kasance a cikin mata masu shekaru 18 zuwa 48, kwanaki 6 zuwa 13 bayan sun karɓi maganin guda ɗaya, a cewar FDA da CDC.

CVST wani nau'in bugun jini ne da ba kasafai ba, a cewar Johns Hopkins Medicine. (ICYDK, bugun jini yana bayyana ainihin yanayin da "jinin da ke samar da sashin kwakwalwar ku ya katse ko rage shi, yana hana nama na kwakwalwa samun iskar oxygen da abinci mai gina jiki," a cewar Mayo Clinic.) CVST yana faruwa ne lokacin da jini ya tashi a cikin jini. sinuses na venous na kwakwalwa (aljihu a tsakanin manyan lamuran kwakwalwa), wanda ke hana zubar jini daga kwakwalwa. Lokacin da jini ya kasa zubewa, zubar jini zai iya tasowa, ma'ana jini na iya fara zubowa cikin kyallen kwakwalwa. Alamomin CVST sun hada da ciwon kai, hangen nesa, suma ko rasa hayyacinsu, asarar sarrafa motsi, kamewa, da kuma suma, a cewar John Hopkins Medicine. (Mai alaƙa: Yaya Tallafin COVID-19 yake da inganci?)

Ganin ƙarancin adadin rahotannin CVST na duk mutanen da suka karɓi rigakafin Johnson & Johnson COVID-19, kuna iya yin mamakin ko CDC da martanin FDA wuce gona da iri ne. Gaskiyar cewa ƙin jini da ƙaramin platelet ya faru a haɗe shine abin da ya sa waɗannan shari'o'in suka zama sananne, in ji Peter Marks, MD, Ph.D., darektan Cibiyar Nazarin Halittu da Bincike ta FDA, a cikin taron manema labarai. "Abin da suka faru tare ne ya samar da tsari kuma tsarin ya yi kama da abin da aka gani a Turai tare da wani maganin," in ji shi. Wataƙila Dakta Marks yana magana ne kan allurar AstraZeneca, ganin cewa ƙasashe da yawa a Turai sun ɗan dakatar da amfani da allurar a watan da ya gabata saboda rahotannin ɗimbin jini da ƙarancin platelet.

Yawanci, ana amfani da maganin coagulant da ake kira heparin don magance ƙin jini, a cewar sanarwar haɗin gwiwa na CDC da FDA. Amma heparin na iya haifar da raguwar matakan platelet, don haka yana iya zama haɗari idan aka yi amfani da shi don kula da mutanen da ke da ƙarancin ƙimar platelet, kamar a yanayin mata shida da ke da lamuran J & J. Dakatar da yin amfani da maganin wani yunƙuri ne na "tabbatar da cewa masu ba da magani sun san cewa idan sun ga mutanen da ke da ƙananan jini, ko kuma idan sun ga mutanen da ke da gudan jini, suna buƙatar yin tambaya game da tarihin rigakafin kwanan nan sannan su yi aiki. bisa ga ganewar asali da kuma kula da waɗannan mutane," in ji Dokta Marks yayin taƙaitaccen bayanin.

Yana da mahimmanci a lura cewa kawai saboda CDC da FDA sun ba da shawarar "dakata" ba lallai ba ne cewa za a dakatar da gudanar da maganin rigakafin Johnson & Johnson gaba ɗaya. "Muna ba da shawarar da a dakatar da allurar ta fuskar gudanar da ayyukanta," in ji Dokta Marks yayin taƙaitaccen bayanin. "Duk da haka, idan mai bada sabis na kiwon lafiya ya tattauna da wani mara lafiya kuma sun yanke shawara cewa fa'ida/haɗarin ga wannan mara lafiyar ya dace, ba za mu dakatar da wannan mai ba da allurar rigakafin ba." Fa'idodin za su fi haɗarin haɗari a cikin "mafi yawan lokuta," in ji shi.

Idan kun kasance ɗayan miliyoyin Amurkawa waɗanda suka riga sun karɓi allurar Johnson da Johnson, kada ku firgita. "Ga mutanen da suka sami allurar fiye da wata guda da suka gabata, haɗarin ya yi ƙasa sosai a wannan lokacin," in ji Anne Schuchat, MD, babbar darektan CDC, ita ma yayin taron manema labarai. "Ga mutanen da kwanan nan suka sami maganin a cikin makonni biyun da suka gabata, ya kamata su sani don duba duk wata alamar cututtuka. Idan kun sami maganin kuma kuka kamu da ciwon kai mai tsanani, ciwon ciki, ciwon ƙafa, ko rashin ƙarfi, ya kamata ku tuntuɓi likitan ku. mai kula da lafiya da neman magani. " (Mai alaƙa: Za ku iya yin aiki bayan samun rigakafin COVID-19?)

Bayanai a cikin wannan labarin daidai ne har zuwa lokacin da ake bugawa. Koyaya, yayin da yanayin da ke kewaye da COVID-19 ke ci gaba da haɓaka, yana yiwuwa wasu bayanan sun canza tun lokacin bugawa. Yayin da Lafiya ke ƙoƙarin ci gaba da sabunta labarun mu kamar yadda zai yiwu, muna kuma ƙarfafa masu karatu su ci gaba da sanar da su labarai da shawarwari ga al'ummominsu ta hanyar amfani da CDC, WHO, da sashin kula da lafiyar jama'a na gida a matsayin albarkatu.

Bita don